Clinical trial
An Open-Label, Multicenter, Randomized Phase II Study to Evaluate the Efficacy and Safety of Personalized Dendritic Cell Vaccine ZSNeo-DC1.1 in Combination With Temozolomide as Adjuvant Therapy in Patients With Newly Diagnosed Glioblastoma After Surgery and Concurrent Chemoradiotherapy
NCT07365280 is registered in ClinicalTrials.gov with ZSky Biotech Inc as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- An Open-Label, Multicenter, Randomized Phase II Study to Evaluate the Efficacy and Safety of Personalized Dendritic Cell Vaccine ZSNeo-DC1.1 in Combination With Temozolomide as Adjuvant Therapy in Patients With Newly Diagnosed Glioblastoma After Surgery and Concurrent Chemoradiotherapy
- Lead sponsor
- ZSky Biotech Inc
- Phase
- Phase 2
- Overall status
- Not yet recruiting
- Start date
- January 9, 2026
- Completion date
- December 24, 2028
- Enrollment
- 78 (estimated)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.